AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23704713
Drug: Vildagliptin (DPP4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (DPP4 inhibitor) during OGTT
Trial: 23704713
Drug: Isoglycaemic i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoglycaemic i.v. glucose infusion (IIGI)
Trial: 19138452
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy in addition to standard medical therapy (prednisolone starting at 1 mg/kg)
Trial: 19138452
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (prednisolone starting at 1 mg/kg)
Trial: 16523808
Drug: Radiotherapy dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy dose of 60 Gy in 30 fractions
Trial: 16523808
Drug: Radiotherapy dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy dose of 74 Gy at 2 Gy/fraction
Trial: 16523808
Drug: Surviving fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surviving fraction of tumour cells after a radiation dose of 2 Gy (SF2)
Trial: 11522564
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg elemental Zinc daily for 5 months
Trial: 29113874
Drug: d-fenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (30 mg, p.o.)
Trial: 2906887
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg terfenadine-120 mg pseudoephedrine hydrochloride combination
Trial: 2906887
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg pseudoephedrine hydrochloride (extended release)
Trial: 28668627
Drug: 3.0g vigabatrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0g vigabatrin solution
Trial: 28668627
Drug: 6.0g vigabatrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.0g vigabatrin solution
Trial: 28668627
Drug: Placebo vigabatrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vigabatrin solution
Trial: 25904205
Drug: PPNa-DBS combined
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPNa-DBS combined with levodopa treatment
Trial: 23556334
Drug: Posaconazole suspension
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole suspension administered orally in the fasted state
Trial: 23556334
Drug: Posaconazole suspension
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole suspension administered orally with a high-fat meal
Trial: 2423652
Drug: CVPP, ABOS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVPP, ABOS, CVPP/ABOS (all treatments)
Trial: 2423652
Drug: Complete responders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete responders (all treatments)
Trial: 20400651
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg (first dose 200 mg) twice daily for 5 days
Trial: 15260882
Drug: 100 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg/day vitamin D
Trial: 15260882
Drug: 15 mcg/day
RxNorm normalized name: estradiol 45 MCG / levonorgestrel 15 MCG/Day Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mcg/day vitamin D
Trial: 15260882
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of vitamin D
Trial: 11429371
Drug: Topical Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Anesthesia
Trial: 11429371
Drug: Cuff Volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuff Volume (10 mL or 30 mL)
Trial: 11429371
Drug: LMA vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMA vs PLMA at 30 mL cuff volume
Trial: 8249871
Drug: Gradually increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradually increasing amounts of lactose in milk until maximum lactose dose tolerated was determined.
Trial: 8249871
Drug: Breath-hydrogen tests
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath-hydrogen tests with the maximum dose of lactose tolerated.
Trial: 3436031
Drug: Oral mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mixed grass‐maize pollen extract
Trial: 28650526
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (30 mg)
Trial: 28650526
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (30 mg)
Trial: 28650526
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (30 mg)
Trial: 19624856
Drug: NOP‐47 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOP‐47 (5 g/day for 2 weeks)
Trial: 1380588
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine (20 mg b.i.d.) and doxazosin (2 mg o.d.)
Trial: 8491245
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine and doxazosin
Trial: 3904643
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) administered intravenously at 10 ng/kg/min for 72 hours
Trial: 3904643
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously for 72 hours
Trial: 30949987
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg twice a day)
Trial: 29528914
Drug: Cell culture-derived
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell culture-derived subunit trivalent inactivated influenza vaccine (NBP607)
Trial: 29528914
Drug: Egg-based control
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-based control vaccine
Trial: 15950492
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg daily for 30 days
Trial: 11920396
Drug: Anakinra 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 1.0 mg/kg + MTX
Trial: 11920396
Drug: Anakinra 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 2.0 mg/kg + MTX
Trial: 11920396
Drug: Anakinra (0.04,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (0.04, 0.1, 0.4 mg/kg) + MTX
Trial: 10796060
Drug: Terbutaline delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at 22 degrees C
Trial: 10796060
Drug: Terbutaline delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C
Trial: 10796060
Drug: Terbutaline delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C after 2000 microg
Trial: 8697553
Drug: Neostigmine (dose-dependent)
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine (dose-dependent)
Trial: 1317272
Drug: Atropine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1.2 mg)
Trial: 6734078
Drug: Biliary excretion
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biliary excretion of radioactive labelled sulphated bile acids
Trial: 31298357
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene session
Trial: 29496516
Drug: DHEA+estrogen/progestin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA+estrogen/progestin therapy
Trial: 25872641
Drug: Participant-customised nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant-customised nutrition education programme (8 weekly sessions of 2-2.5 hours)
Trial: 20718773
Drug: NNC126‐0083 (0·02,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC126‐0083 (0·02, 0·04, 0·08 and 0·16 mg protein/kg)
Trial: 17504357
Drug: Sodium picosulphate
RxNorm normalized name: Sodium Picosulfate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium picosulphate (7 mg for three consecutive nights)
Trial: 15258718
Drug: venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine ER fixed low dose (75 mg/day)
Trial: 15258718
Drug: venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine ER flexible higher dose (150-225 mg/day)
Trial: 15258718
Drug: venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine ER (at any dose)
Trial: 10910491
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg meperidine
Trial: 9261669
Drug: High-dose pyridoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pyridoxine and magnesium (HDPM) at an average dose of 638.9 mg of pyridoxine and 216.3 mg of magnesium oxide
Trial: 8275623
Drug: Oral physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral physostigmine salicylate
Trial: 3325468
Drug: IFN‐beta‐containing cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐beta‐containing cream
Trial: 25468685
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (candy corn)
Trial: 25880068
Drug: Indapamide sustained
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide sustained release 1.5 mg ± perindopril 2 to 4 mg
Trial: 16239059
Drug: Gingicain Spray
RxNorm normalized name: Gingicaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gingicain Spray
Trial: 16239059
Drug: Gingicaine Topical
RxNorm normalized name: Gingicaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gingicaine Topical Anesthetic
Trial: 11139801
Drug: Oral glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycoprotein IIb/IIIa antagonists
Trial: 3944837
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with daily hydrotherapy and twice daily applications of topical antimicrobial agents until granulating beds could receive autografts
Trial: 22364823
Drug: Labetalol 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 0.4 mg/kg IV (prevention)
Trial: 22364823
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 μg/kg IV (prevention)
Trial: 22364823
Drug: Labetalol 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 0.4 mg/kg IV (treatment)
Trial: 22364823
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 μg/kg IV (treatment)
Trial: 20843249
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (initial doses based on weight)
Trial: 20843249
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (higher doses)
Trial: 12525526
Drug: Chemotherapy arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy arm (cisplatin and fluorouracil followed by surgery)
Trial: 10967380
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment combining polypectomy, intra‐maxillary intubation through the inferior meatus, macrolide administration
Trial: 8317002
Drug: Electronic rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic rectal temperature measurement with Ivac thermometer
Trial: 8317002
Drug: Electronic rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic rectal temperature measurement with Ivac thermometer after calibration
Trial: 3545909
Drug: Methylprednisolone (96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (96 mg in three divided doses for 7 days followed by a 2-day tapering)
Trial: 25591391
Drug: Sulphadoxine‐pyrimethamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadoxine‐pyrimethamine plus azithromycin (SPAZ) monthly from second trimester
Trial: 23429964
Drug: Inhaled dry
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dry powder mannitol 320 mg bid for 12 weeks
Trial: 23429964
Drug: Inhaled dry
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dry powder mannitol 320 mg bid for 12 weeks (subgroup study)
Trial: 18811806
Drug: Primary implants
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary implants for LBBB
Trial: 12911281
Drug: New AChR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New AChR antibody test using a mixture of AChR from TE671‐ε and TE671‐γ cells
Trial: 9121823
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of analgesics (opioids and NSAIDs)
Trial: 1848392
Drug: Lisinopril (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (equal milligram dosage)
Trial: 1848392
Drug: Enalapril (constant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (constant dosage)
Trial: 1848392
Drug: Lisinopril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (5 mg tablet per day)
Trial: 1848392
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg tablet per day)
Trial: 1848392
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg tablet per day)
Trial: 6653136
Drug: Conventional capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional capsules (600 mg disopyramide in 3 divided doses)
Trial: 6653136
Drug: Conventional capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional capsules (500 mg disopyramide daily for 11 days)
Trial: 6653136
Drug: Sustained-release tablets
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablets (500 mg disopyramide daily for 11 days)
Trial: 6653136
Drug: Sustained-release tablets
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablets (500 mg disopyramide daily for 30 days)
Trial: 6653136
Drug: Disopyramide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide treatment
Trial: 6653136
Drug: Disopyramide sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide sustained-release tablets
Trial: 30517586
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery relaxation therapy
Trial: 24419112
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy plus hypnosis (CBTH)
Trial: 22442025
Drug: IPC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPC treatment
Trial: 20465893
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy for one week
Trial: 20465893
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy for two weeks
Trial: 20465893
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy for four weeks
Trial: 17468821
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ropivacaine
Trial: 17468821
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ropivacaine
Trial: 14699453
Drug: Miltefosine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miltefosine (2.5 mg/kg per day for 28 days)
Trial: 8792486
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg) twice daily for 10 days
Trial: 8792486
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily for 10 days
Trial: 29290547
Drug: Condition 2
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condition 2 (room without acoustic treatment with noise reproduction)
Trial: 29290547
Drug: Condition 1
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condition 1 (room without acoustic treatment and without noise reproduction)
Trial: 29020983
Drug: AZD5069 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5069 (40 mg) administered orally twice daily for 24 weeks
Trial: 26501236
Drug: Systemic corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroid therapy
Trial: 16968726
Drug: Subcutaneous epoetin-alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin-alpha (SC-EPO; EPREX; 1000 U twice weekly)
Trial: 16968726
Drug: Subcutaneous epoetin-alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin-alpha (SC-EPO; 2000 U three times weekly)
Trial: 16287442
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL lidocaine‐prilocaine cream
Trial: 11888953
Drug: Montelukast, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, 10 mg, once daily for 4 weeks
Trial: 11888953
Drug: Placebo tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, once daily for 4 weeks
Trial: 7825527
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g fine coffee grounds per day for 3 weeks
Trial: 31988276
Drug: Preoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment and surgical resection (multimodal treatment).
Trial: 31236679
Drug: Uncomplicated acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncomplicated acute appendicitis (surgical treatment arm of the APPAC trial)
Trial: 28464867
Drug: Behaviour change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour change communication (BCC) on maternal nutrition during pregnancy, exclusive breastfeeding, and complementary feeding, along with prenatal nutritional supplement (PNS) and complementary food supplement (CFS)
Trial: 23218022
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus low-dose risperidone
Trial: 23218022
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus placebo
Trial: 23218022
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy plus placebo
Trial: 11697643
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies involving vaccines
Trial: 9549738
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 2 mg.kg‐1
Trial: 9549738
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 2 mg.kg‐1
Trial: 9115058
Drug: Alprazolam 4
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam 4 mg
Trial: 9115058
Drug: Alprazolam 8
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam 8 mg
Trial: 9115058
Drug: Alprazolam 10
RxNorm normalized name: alprazolam 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 10 mg